GH Research Announces Appointment of Vanina Popova, MD, as Chief Development Officer
DUBLIN, Nov. 13, 2026 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression, today announced the appointment of Vanina Popova, MD, as Chief Development Officer, to lead the clinical development of GH001 into our pivotal programs in treatment-resistant depression (TRD) and postpartum depression (PPD).
Covered in this story
Call it yourself
No calls on $GHRS yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on GH Research →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.